Live
Endpoints NewsHealth groups say HHS is trying to 'rush reinstatement' of ACIPEndpoints NewsB cell therapy maker Be Bio stops hemophilia trialClinical OMICsFibroblast Signaling Pathways Linked to Angiogenesis Differences in NSCLCEndpoints NewsFDA raises no major red flags with Moderna's flu shotFierceBiotechEli Lilly’s M&A spree continues with acquisition of non-opioid pain drugmaker 4EFierceBiotechAmenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grillingClinical OMICsMini Brains Help Identify Treatment for Rare Form Parkinson’s DiseaseEndpoints NewsFDA greenlights Colorado's drug import proposalCellThe critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBMFierceBiotechPE firm Altaris scoops up AI drug development outfit Simulations Plus for $375MBioPharma DiveLilly buys non-opioid pain drugmaker 4EBioPharma DiveExpress Scripts, PCMA sue to block Tennesee law breaking up PBMs and pharmacies
Thermo Fisher Feb 1, 2026

Thermo Fisher Scientific Earnings Call Highlights Steady Growth - TipRanks

Thermo Fisher Scientific Earnings Call Highlights Steady Growth - TipRanks

Original
Body unavailable. Use the original source.